Search

Displaying results 1311 - 1320 of 4344 in total
  1. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.

    Products: OPDIVO® 40MG/4ML., Opdivo 10mg/ml, Concentrate for solution for infusion
  2. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

    Products: TORASEMID AAA 20MG, Demadex Tablets - 10mg
  3. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.

  4. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

  5. Drug

    Tetradecyl hydrogen sulfate (ester)

    go.drugbank.com/drugs/DB11328
    Approved

    Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodiu...

  6. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  7. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54783] Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.[A275293] … [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and

  8. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    It was originally approved by the U.S.

    Products: RITOXEN 10MG/ML, IXIMAB® 10MG/ML
  9. Drug

    Cefadroxil

    go.drugbank.com/drugs/DB01140
    ApprovedInvestigationalVet approvedWithdrawn

    Long-acting, broad-spectrum, water-soluble, cephalexin derivative.

  10. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.